Patents 4 Patients Establishes a Fast-Track Review for Cancer Treatment-Related Patents

This free, accelerated initiative will launch in July and cut in half the time it takes to review patent applications in cancer therapy (aiming to have final decisions made in 12 or fewer months). This "fast track" will be open to any applicant, including early stage bio-tech companies, universities, and large pharmaceutical firms, as well as entities who may have products already in FDA approved clinical trials, which will also be able to opt in to the acceleration program, even if they have a patent application already filed with the office. With approximately 900 cancer immunotherapy applications received annually by the USPTO, and from around the world, this program aims to move innovative new treatments from conception through regulatory approval swiftly, to reach a patient's bedside faster.

For more information about the USPTO’s Patents 4 Patients program, please refer to the Federal Register Notice.

“As ailments of all types afflict our families, our neighbors, and our loved ones, piloting this initiative marks an important first step in testing and assessing how faster patent protection, in concert with swifter reviews from other regulatory bodies, can mark a collective approach that works to break down barriers to progress impeding cancer research,” said Lee.

Read the full press release on the USPTO website.